Acute Myeloid Leukemia Real World Treatment Patterns

Sponsor
Pfizer
Study ID
NCT04230564
Status
Withdrawn

Conditions

  • Leukemia, Myeloid, Acute

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • azacitidine — DRUG
    Patients taking azacitidine
  • venetoclax — DRUG
    patients taking venetoclax
  • glasdegib — DRUG
    patients taking glasdegib

Study Details

Among patients with a diagnosis of AML who received non-intensive chemotherapy: * Describe patient demographic and clinical characteristics * Describe treatment patterns * Describe effectiveness outcomes * Evaluate tumor response

Key Dates

First listed
Jan 18, 2020
Start date
Oct 31, 2020
Status verified
Feb 2021
Primary completion
Mar 31, 2021
Completion
Mar 31, 2021

Study Design

Enrollment
0 participants (actual)

Arms

  • Arm: AML
    Patients diagnosed with AML

Primary Outcome Measure

Overall Survival [ Time Frame: January 1, 2012 to January 10, 2020 ]

Related Studies